In:
Journal of İzmir Chest Hospital, Kare Publishing, ( 2021)
Kurzfassung:
In December 2019, severe acute respiratory diseases due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were reported from Wuhan province of China. The symptoms associated with Coronavirus Disease-2019 (COVID-19) range from mild upper respiratory tract infection to acute respiratory distress syndrome (ARDS). It was observed that symptoms and radiological findings continued in some patients after discharge. Comorbidities such as hypertension and diabetes, risk factors such as male gender and advanced age are common risk factors for severe COVID-19 and idiopathic pulmonary fibrosis (IPF). However, the role of anti fibrotictherapy and the scientific rationale for their continuation or discontinuation in IPF patients infected with SARS-CoV-2 have not been fully defined. Data from the COVID-19 pandemic and previous coronavirus infections such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) suggest that there may be significant fibrotic changes following SARS-CoV-2 infection. In this article, the frequency of on going symptoms after COVID-19 pneumonia and the frequency of interstitial lung disease that may ocur were discussed. Inaddition, the prevention of interstitial changes in the lung, especially pulmonary fibrosis, and the decrease in respiratory functions are discussed in the light of the literature.
Materialart:
Online-Ressource
ISSN:
1300-4115
Originaltitel:
COVİD-19 Sonrası Devam Eden Semptomlar, İnterstisyel Akciğer Hastalığı Oluşumu ve Takip Süreci
DOI:
10.5222/IGH.2021.00719
Sprache:
Unbekannt
Verlag:
Kare Publishing
Publikationsdatum:
2021
Permalink